Inclusion Criteria:
  -  the ability to understand the informed consent form, and the signing the informed consent form after being informed in detail,
  -  planned to have ≥3 cycles of neurotoxic chemotherapy (paclitaxel, docetaxel from taxane class agents, and cisplatin, oxaliplatin or carboplatin from platin group),
  -  expected to have a survival of ≥6 months,
  -  to have an Eastern Cooperative Oncology Group performance level between 0-2,
  -  to have a full manual muscle strength.
Exclusion Criteria:
  -  Previously diagnosed peripheral neuropathy (Diabetic peripheral neuropathy, entrapment neuropathies etc.)
  -  Patients receiving medical treatment due to neuropathic pain (pregabalin, gabapentin, duloxetine etc.)
  -  Pre-existing neurological disease
  -  Pre-existing diabetes mellitus (>3 years or insulin use)
  -  Alcoholism
  -  HIV infection
  -  Presence of peripheral vascular disease
  -  Vitamin D or vitamin B12 deficiency
  -  Non-ambulatory or refuse to practice exercise program
  -  Visual or vestibular system impairment
  -  Patients with central nervous system involvement or metastasis